Short- and long-term risk of cardiovascular events in white-coat hypertension

Journal of Human Hypertension

Volumn 22, Issue 6, 2008, Pages 408-414

  Pierdomenico, S D ^a   Lapenna, D ^a   Di Mascio, R ^a   Cuccurullo, F ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; FATALITY; FEMALE; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE; STROKE; SURVIVAL RATE; WHITE COAT HYPERTENSION;

ADULT; AGED; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS; STROKE; TIME FACTORS;

EID: 44049103972     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.6     Document Type: Article

References (27)

1. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white-coat hypertension? JAMA 1988; 259: 225-228.
2. Pierdomenico SD, Mezzetti A, Lapenna D, Guglielmi MD, Mancini M, Salvatore L et al. White-coat hypertension in patients with newly diagnosed hypertension: Evaluation of prevalence by ambulatory monitoring and impact on cost of health care. Eur Heart J 1995; 16: 692-697.
3. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801.
4. Fagard RH, Staessen JA, Thijs L, Gasowski J, Bulpitt CJ, Clement D et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Circulation 2000; 102: 1139-1144.
5. Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshide S, Pickering TG. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Am Coll Cardiol 2001; 38: 238-245.
6. Celis H, Staessen JA Thijs L, Buntinx F, De Buyzere M, Den Hond E et al. Cardiovascular risk in white-coat and sustained hypertension. Blood Press 2002; 11: 352-356.
7. Pierdomenico SD, Lapenna D, Bucci A, Di Iorio A, Neri M, Cuccurullo F et al. Cardiovascular and renal events in uncomplicated mild hypertensive patients with sustained and white coat hypertension. Am J Hypertens 2004; 17: 876-881.
8. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: A 10-year follow-up study. Circulation 1998; 98: 1892-1897.
9. Fagard RH, Van den Broeke C, De Cort P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J Hum Hypertens 2005; 19: 801-807.
10. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J et al Prognosis of masked hypertension and white coat hypertension detected by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol 2005; 46: 508-515.
11. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pederesen C. Ambulatory blood pressure monitoring and risk of cardiovascular disease. A population based study. Am J Hypertens 2006; 19: 243-250.
12. Strandberg TE, Salomaa V. White coat effect, blood pressure and mortality in men: Prospective cohort study. Eur Heart J 2000; 21: 1714-1718.
13. Gustavsen PH, Hoegholm A, Bang LE, Kristensen KS. White coat hypertension is a cardiovascular risk factor: A 10-year follow-up study. J Hum Hypertens 2003; 17: 811-817.
14. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension 2005; 45: 203-208.
15. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-tem risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006; 47: 846-853.
16. Pierdomenico SD, Lapenna D, Guglielmi MD, Antidormi T, Schiavone C, Cuccurullo F et al. Target organ status and serum lipids in patients with white coat hypertension. Hypertension 1995; 26 801-807.
17. Pickering TG. Recommendations for the use of home (self) and ambulatory blood pressure monitoring. Am J Hypertens 1996; 9: 1-11.
18. Sahn DJ, DeMaria A, Kisslo J, Weyman A, for the Committee an M-mode standardization of the American Society of Echocardiogrqphy. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
19. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
20. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: Assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25: 1056-1062.
21. McKee PA, Castelli WP, McNamara PM, Kennel WB. The natural history of congestive heart failure. N Engl J Med 1971; 285: 1441-1446.
22. Altman DG. Practical Statistits for Medical Research, 1st edn. Chapman & Hall: London, 1991, 365 pp.
23. Verdecchia P, Staessen JA, White WB, Imai Y, O'Brien ET. Properly defining white coat hypertension. Eur Heart J 2002; 23: 106-109
24. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Sacchi N et al. Identification of subjects with white-coat hypertension and persistently normal ambulatory blood pressure. Blood Press Monit 1996; 1: 217-222.
25. Polonia JJ, Santos AR, Gama GM, Basto F, Bettencourt PM, Martins LR. Follow-up clinic and ambulatory blood pressure in untreated white-coat hypertensive patients (evaluation after 2-5 years). Blood Press Monit 1997; 2: 289-295.
26. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens 2007; 25: 2193-2198.
27. Pickering TG, Levenstein M, Walmsley P. Differential effects of doxazosin on clinic and ambulatory blood pressure according to age, gender and presence of white coat hypertension. Am J Hypertens 1994; 7: 848-852.